Literature DB >> 28377400

Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059.

Harriet S Walter1, Sandrine Jayne1, Simon A Rule2, Guillaume Cartron3, Franck Morschhauser4,5, Salvador Macip1, Lionel Karlin6, Ceri Jones7, Charles Herbaux4,5, Philippe Quittet3, Nimish Shah2, Claire V Hutchinson1,2, Christopher Fegan7, Yingsi Yang8, Siddhartha Mitra8, Gilles Salles6, Martin J S Dyer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28377400      PMCID: PMC5437828          DOI: 10.1182/blood-2017-02-765115

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  16 in total

Review 1.  B cell receptor inhibition as a target for CLL therapy.

Authors:  Deepa Jeyakumar; Susan O'Brien
Journal:  Best Pract Res Clin Haematol       Date:  2016-08-11       Impact factor: 3.020

2.  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Authors:  Jennifer A Woyach; Kelly Smucker; Lisa L Smith; Arletta Lozanski; Yiming Zhong; Amy S Ruppert; David Lucas; Katie Williams; Weiqiang Zhao; Laura Rassenti; Emanuela Ghia; Thomas J Kipps; Rose Mantel; Jeffrey Jones; Joseph Flynn; Kami Maddocks; Susan O'Brien; Richard R Furman; Danelle F James; Fong Clow; Gerard Lozanski; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

3.  The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo.

Authors:  Sabine Ponader; Shih-Shih Chen; Joseph J Buggy; Kumudha Balakrishnan; Varsha Gandhi; William G Wierda; Michael J Keating; Susan O'Brien; Nicholas Chiorazzi; Jan A Burger
Journal:  Blood       Date:  2011-12-16       Impact factor: 22.113

4.  Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Jan A Burger; Kristie A Blum; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Yun Shaw; Elizabeth Bilotti; Cathy Zhou; Danelle F James; Susan O'Brien
Journal:  Blood       Date:  2015-02-19       Impact factor: 22.113

5.  Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies.

Authors:  Ranjana H Advani; Joseph J Buggy; Jeff P Sharman; Sonali M Smith; Thomas E Boyd; Barbara Grant; Kathryn S Kolibaba; Richard R Furman; Sara Rodriguez; Betty Y Chang; Juthamas Sukbuntherng; Raquel Izumi; Ahmed Hamdy; Eric Hedrick; Nathan H Fowler
Journal:  J Clin Oncol       Date:  2012-10-08       Impact factor: 44.544

6.  Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.

Authors:  Kerstin Trunzer; Anna C Pavlick; Lynn Schuchter; Rene Gonzalez; Grant A McArthur; Thomas E Hutson; Stergios J Moschos; Keith T Flaherty; Kevin B Kim; Jeffrey S Weber; Peter Hersey; Georgina V Long; Donald Lawrence; Patrick A Ott; Ravi K Amaravadi; Karl D Lewis; Igor Puzanov; Roger S Lo; Astrid Koehler; Mark Kockx; Olivia Spleiss; Annette Schell-Steven; Houston N Gilbert; Louise Cockey; Gideon Bollag; Richard J Lee; Andrew K Joe; Jeffrey A Sosman; Antoni Ribas
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

Review 7.  Clinical implications of the molecular genetics of chronic lymphocytic leukemia.

Authors:  Robin Foà; Ilaria Del Giudice; Anna Guarini; Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2013-05       Impact factor: 9.941

8.  A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies.

Authors:  Harriet S Walter; Simon A Rule; Martin J S Dyer; Lionel Karlin; Ceri Jones; Bruno Cazin; Philippe Quittet; Nimish Shah; Claire V Hutchinson; Hideyuki Honda; Kevin Duffy; Joseph Birkett; Virginia Jamieson; Nigel Courtenay-Luck; Toshio Yoshizawa; John Sharpe; Tomoya Ohno; Shinichiro Abe; Akihisa Nishimura; Guillaume Cartron; Franck Morschhauser; Christopher Fegan; Gilles Salles
Journal:  Blood       Date:  2015-11-05       Impact factor: 22.113

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

View more
  17 in total

Review 1.  Targeted Therapy in Chronic Lymphocytic Leukemia.

Authors:  Thomas J Kipps; Michael Y Choi
Journal:  Cancer J       Date:  2019 Nov/Dec       Impact factor: 3.360

Review 2.  Experience with ibrutinib for first-line use in patients with chronic lymphocytic leukemia.

Authors:  Gilad Itchaki; Jennifer R Brown
Journal:  Ther Adv Hematol       Date:  2017-11-28

Review 3.  Targeting Bruton's Tyrosine Kinase Across B-Cell Malignancies.

Authors:  Caspar da Cunha-Bang; Carsten Utoft Niemann
Journal:  Drugs       Date:  2018-11       Impact factor: 9.546

Review 4.  Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Authors:  Fabienne Lucas; Jennifer A Woyach
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

5.  Oral Bruton tyrosine kinase inhibitors block activation of the platelet Fc receptor CD32a (FcγRIIA): a new option in HIT?

Authors:  Luise Goldmann; Rundan Duan; Thorsten Kragh; Georg Wittmann; Christian Weber; Reinhard Lorenz; Philipp von Hundelshausen; Michael Spannagl; Wolfgang Siess
Journal:  Blood Adv       Date:  2019-12-10

Review 6.  The Treatment of Chronic Lymphatic Leukemia.

Authors:  Julia von Tresckow; Barbara Eichhorst; Jasmin Bahlo; Michael Hallek
Journal:  Dtsch Arztebl Int       Date:  2019-01-25       Impact factor: 5.594

Review 7.  Managing toxicities of Bruton tyrosine kinase inhibitors.

Authors:  Andrew Lipsky; Nicole Lamanna
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2020-12-04

8.  Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.

Authors:  Wataru Munakata; Kiyoshi Ando; Kiyohiko Hatake; Noriko Fukuhara; Tomohiro Kinoshita; Suguru Fukuhara; Yukari Shirasugi; Masahiro Yokoyama; Satoshi Ichikawa; Ken Ohmachi; Naokazu Gion; Arata Aoi; Kensei Tobinai
Journal:  Cancer Sci       Date:  2019-03-28       Impact factor: 6.716

Review 9.  Recent therapeutic advances in chronic lymphocytic leukemia.

Authors:  Prithviraj Bose; Varsha Gandhi
Journal:  F1000Res       Date:  2017-10-31

10.  BTK: a two-faced effector in cancer and tumour suppression.

Authors:  Miran Rada; Nickolai Barlev; Salvador Macip
Journal:  Cell Death Dis       Date:  2018-10-18       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.